Vanguard Dividend Appreciation Index Fund ETF vs Zoetis Inc — how do they compare? Vanguard Dividend Appreciation Index Fund ETF trades at $239.15 (market cap $132.40B), while Zoetis Inc trades at $74.43 (market cap $30.20B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 4.4× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Dividend Appreciation Index Fund ETF for 134 Days and Zoetis Inc for 70 Days on average.
| VIG | ZTS | |
|---|---|---|
Market Cap | $132.40B | $30.20B |
Volume | 1,287,188 | 6,175,327 |
52-Week High | $246.61 | $147.53 |
52-Week Low | $210.70 | $69.09 |
Typical Hold Time | 134 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
VIG trades at $239.00, up 0.85% with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights its role in retirement portfolios and a 7.5% quarterly dividend increase, though year-to-date growth remains modest at 3.3%.
Outlook remains positive given VIG's quality focus and historical 10% annual returns, but risks include slow dividend growth and exclusion of high-yield stocks. The ETF suits investors seeking steady income with growth potential, though competition from SCHD and market volatility pose challenges to outperformance.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →